
Lonza Invests for Biopharma Customer at Visp
Swiss CDMO Lonza is investing 200 million Swiss francs at its Alpine site in Visp to build a new manufacturing complex for a long-term biopharmaceutical manufacturing partner. Lonza said the project is being supported by an unquantified capital contribution from the undisclosed partner.









































